Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag and a Flag tag at the C-terminus. The protein has a calculated MW of 69.5 kDa.
>90% as determined by SDS-PAGE.
This product is not suitable for cell based experiments due to cytotoxicity of DDM.
DDM and CHS are INDISPENSABLE to keep membrane protein soluble and active, under no circumastance should you remove DDM and CHS.
DDM/CHS buffer (DC-11) is sold separately and not included in protein, and please contact us if you need the buffer.
If glycerol is not compatible to your application, remove glycerol just before immediate experiment, and NEVER store glycerol-free protein solution.
Supplied as 0.2 μm filtered solution in 50 mM HEPES, 150 mM NaCl, DDM, CHS, pH7.5 with glycerol as protectant.
Contact us for customized product form or formulation.
This product is supplied and shipped with dry ice, please inquire the shipping cost.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Immobilized Human GIPR Protein, His,Flag Tag (Cat. No. GIR-H52D3) at 10 μg/mL (100 μL/well) on Nickel Coated plates (Cat. No. SP-19) can bind Anti-GIPR Antibody with a linear range of 1-63 ng/mL (QC tested).
Price(USD) : $805.00
Price(USD) : $2985.00
Price(USD) : $7480.00
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Tirzepatide | LY-3298176; GIP/GLP-1 RA | Approved | Eli Lilly And Company | Mounjaro, Zepbound, 穆峰达 | United States | Diabetes Mellitus, Type 2 | Eli Lilly And Company | 2022-05-13 | Metabolic Diseases; Nutritional and Metabolic Diseases; Kidney Failure, Chronic; Diabetes Mellitus; Overweight; Renal Insufficiency, Chronic; Obesity; Alcoholism; Glucose Metabolism Disorders; Hepatic Insufficiency; Cardiovascular Diseases; Breast Neoplasms; Prostatic Neoplasms; Substance-Related Disorders; Sleep Apnea Syndromes; Endocrine System Diseases; Obesity, Morbid; Hypoglycemia; Opioid-Related Disorders; Sleep Apnea, Obstructive; Weight Gain; Metabolic Dysfunction-Associated Steatotic Liver Disease; Renal Insufficiency; Heart Failure; Diabetes Mellitus, Type 2; Diabetes Mellitus, Type 1 | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Retatrutide | LY-3437943 | Phase 3 Clinical | Eli Lilly And Company | Diabetes Mellitus, Type 2; Atherosclerosis; Renal Insufficiency; Sleep Apnea, Obstructive; Hepatic Insufficiency; Osteoarthritis, Knee; Cardiovascular Diseases; Renal Insufficiency, Chronic; Obesity; Overweight | Details |
BGM-0504 | BGM-0504 | Phase 3 Clinical | Brightgene Bio-Medical Technology Co Ltd | Diabetes Mellitus, Type 2; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Overweight | Details |
HRS-9531 | HRS-9531; HRS9531 | Phase 3 Clinical | Fujian Suncadia Medicine Co Ltd | Heart Failure, Diastolic; Diabetes Mellitus, Type 2; Polycystic Ovary Syndrome; Body Weight; Obesity; Overweight; Diabetes Mellitus | Details |
HS-20094 | HS-20094 | Phase 3 Clinical | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Diabetes Mellitus, Type 2; Obesity; Overweight | Details |
CT-868 | CT-868; RG-6641 | Phase 2 Clinical | Carmot Therapeutics Inc | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Obesity; Overweight | Details |
Efocipegtrutide | HM-15211 | Phase 2 Clinical | Hanmi Pharmaceutical Co Ltd | Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity | Details |
NNC0480-0389 | NNC0480-0389 | Phase 2 Clinical | Novo Nordisk A/S | Diabetes Mellitus, Type 2; Obesity; Overweight | Details |
HDM-1005 | HDM-1005; HDM1005 | Phase 2 Clinical | Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd | Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Obesity; Overweight | Details |
PF-07976016 | PF-07976016 | Phase 2 Clinical | Pfizer Inc | Obesity | Details |
NNC0519-0130 | NNC0519-0130 | Phase 2 Clinical | Novo Nordisk A/S | Diabetes Mellitus, Type 2; Obesity; Renal Insufficiency, Chronic | Details |
MWN-101 | MWN-101 | Phase 2 Clinical | Shanghai Minwei Biotechnology Co Ltd | Diabetes Mellitus, Type 2; Sleep Apnea, Obstructive; Obesity; Overweight | Details |
RAY-1225 | RAY1225; RAY-1225 | Phase 2 Clinical | Guangdong Raynovent Biotech Co Ltd | Diabetes Mellitus, Type 2; Metabolic Dysfunction-Associated Steatotic Liver Disease; Acute Kidney Injury; Hepatic Insufficiency; Obesity; Overweight | Details |
VK-2735 | VK-2735 | Phase 2 Clinical | Viking Therapeutics Inc | Weight Loss; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity | Details |
THDBH-120 | THDBH120; THDBH121 | Phase 2 Clinical | Wuxi Apptec(Shanghai) Co Ltd | Diabetes Mellitus, Type 2; Obesity; Overweight; Diabetes Mellitus | Details |
CT-388 | CT-388; RG-6640 | Phase 2 Clinical | Carmot Therapeutics Inc | Diabetes Mellitus, Type 2; Obesity; Overweight; Diabetes Mellitus | Details |
Maridebart cafraglutide | AMG-133; AMG133 | Phase 2 Clinical | Amgen Inc | Diabetes Mellitus, Type 2; Body Weight; Obesity; Overweight | Details |
LY-3493269 | LY-3493269 | Phase 1 Clinical | Eli Lilly And Company | Diabetes Mellitus, Type 2 | Details |
SCO-094 | SCO-094; tak-094 | Phase 1 Clinical | Takeda | Diabetes Mellitus, Type 2 | Details |
NN9542 | NN9542; NN-9542 | Phase 1 Clinical | Novo Nordisk A/S | Obesity | Details |
Gastric inhibitory polypeptide receptor agonist long acting II therapeutic (Eli Lilly and Company) | Phase 1 Clinical | Eli Lilly And Company | Obesity; Diabetes Mellitus | Details | |
NNC0650-0013 | NNC0650-0013; NN9650; NN-9650 | Phase 1 Clinical | Novo Nordisk A/S | Details | |
ZX-2010 | ZX2010; ZX-2010 | Phase 1 Clinical | Jiangsu Zhongxin Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2; Obesity; Overweight | Details |
MWN-105 | MWN-105 | Phase 1 Clinical | Shanghai Minwei Biotechnology Co Ltd | Diabetes Mellitus, Type 2; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Overweight; Hyperlipidemias | Details |
ZX-2021 | ZX2021; ZX-2021 | Phase 1 Clinical | Jiangsu Zhongxin Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2; Obesity; Overweight | Details |
HZ-012 | DR-10628; HZ-012 | Phase 1 Clinical | Hangzhou Heze Pharmaceutical Technology Co Ltd, Zhejiang Doer Biologics Corp | Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Obesity; Diabetes Mellitus; Overweight | Details |
DR-10627 | HZ-010; DR-10627 | Phase 1 Clinical | Hangzhou Heze Pharmaceutical Technology Co Ltd, Zhejiang Doer Biologics Corp | Diabetes Mellitus, Type 2; Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus | Details |
Macupatide | LY-3532226 | Phase 1 Clinical | Eli Lilly And Company | Diabetes Mellitus, Type 1; Obesity | Details |
LY-3537031 | LY3537031; LY-3537031 | Phase 1 Clinical | Eli Lilly And Company | Obesity; Diabetes Mellitus | Details |
LY-3537021 | LY-3537021 | Phase 1 Clinical | Eli Lilly And Company | Diabetes Mellitus, Type 2 | Details |
GMA-106 | GMA106; GMA-106 | Phase 1 Clinical | Gmax Biopharm Llc | Obesity; Overweight | Details |
GIP[3-30]NH2 | GIP[3-30]NH2 | Copenhagen University Hospital Gentofte, University Of Copenhagen | Details |
This web search service is supported by Google Inc.